Skip to main content
. 2017 Sep 23;8(48):84403–84416. doi: 10.18632/oncotarget.21218

Figure 1. Expressions change of miR-155-3p and MEF2C during ESCs differentiation and effects of miR-155-3p inhibitor on EBs beating and growth.

Figure 1

(A-C) MEF2C mRNA and miR-155-3p were detected by Real-time PCR. MEF2C protein was measured by Western blot. (A) miR-155-3p level in the EBs at d0, d3, d6, d9, and d12 was detected. miR-155-3p was down-regulated during ESCs differentiation. (B) MEF2C mRNA in the EBs at d0, d3, d6, d9, and d12 was detected. MEF2C mRNA was up-regulated during ESCs differentiation. n=6. (C) MEF2C protein in the EBs at d0, d6, and d12 was measured. (D) Data indicated the expression level of MEF2C. MEF2C was significantly up-regulated in d6 group as compared to d0 group. n=5. (E and F) ESCs were stably transfected with miR-155-3p inhibitor. (E) miR-155-3p inhibitor promoted the EBs beating. The percentages of EBs beating were calculated at d10, d12, and d14. n=6. (F) miR-155-3p inhibitor did not change EBs growth. The diameters of EBs were measured at d10, d12, and d14. n=6. Data were showed as mean ± S.D. ***P < 0.001 vs d0 group; #P < 0.05;##P < 0.01, and ###P < 0.001; $$P < 0.01, and $$$P < 0.001 vs control group.